loading...| Preferred Name |
pantoprazole sodium |
|
| Synonyms |
Protonix |
|
| Definitions |
The sodium salt form of a substituted benzimidazole with proton pump inhibitor activity. Pantoprazole is a lipophilic, weak base that crosses the parietal cell membrane and enters the acidic parietal cell canaliculus where it becomes protonated, producing the active metabolite sulfenamide, which forms an irreversible covalent bond with two sites of the H+/K+-ATPase enzyme located on the gastric parietal cell, thereby inhibiting both basal and stimulated gastric acid production. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C61877" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61877" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000682170 |
|
| altLabel |
Protonix |
|
| CAS Registry |
164579-32-2 |
|
| cui |
C0876139 C0795650 |
|
| DATE FIRST PUBLISHED |
2010-07-20 |
|
| Date last modified |
2017-12-18 |
|
| definition |
The sodium salt form of a substituted benzimidazole with proton pump inhibitor activity. Pantoprazole is a lipophilic, weak base that crosses the parietal cell membrane and enters the acidic parietal cell canaliculus where it becomes protonated, producing the active metabolite sulfenamide, which forms an irreversible covalent bond with two sites of the H+/K+-ATPase enzyme located on the gastric parietal cell, thereby inhibiting both basal and stimulated gastric acid production. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C61877" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61877" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C61877 |
|
| notation |
CDR0000682170 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
pantoprazole sodium |
|
| tui |
T109 T121 |